Loading
Vaccine Efficacy / Community Acquired Infections / Respiratory Syncytial Virus Vaccines · review article
Expert Review of Vaccines · July 24, 2026
A consensus or society position rather than new primary data.
This expert review synthesizes current understanding of RSV as a contributor to adult community-acquired pneumonia, highlighting underdiagnosis due to overlapping clinical features and limited routine testing. The authors recommend improved molecular diagnostics, strengthened surveillance, targeted vaccination of high-risk populations, and further research in immunocompromised groups to reduce disease burden.
review article. Adults with community-acquired pneumonia, particularly older adults and those with chronic cardiopulmonary disease.
RSV contributes meaningfully to adult CAP, particularly in older adults and those with chronic cardiopulmonary disease Clinical features overlap with other respiratory infections and routine testing is limited, leading to frequent underdiagnosis Multi-specimen molecular testing improves RSV detection in adults with CAP
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should consider RSV in the differential diagnosis of adult CAP during circulation periods and utilize molecular testing to improve detection. Enhanced diagnosis may support antimicrobial stewardship by reducing unnecessary antibiotic use and inform targeted vaccination strategies for high-risk populations.
A narrative review summarizing diagnostic challenges, clinical consequences, and prevention strategies for adult RSV-associated CAP without primary data or meta-analysis.
As stated by the source record.
Clinicians should consider RSV in the differential diagnosis of adult CAP during circulation periods and utilize molecular testing to improve detection. Enhanced diagnosis may support antimicrobial stewardship by reducing unnecessary antibiotic use and inform targeted vaccination strategies for high-risk populations.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Introduction. Community-acquired pneumonia (CAP) remains a significant cause of adult morbidity and mortality. Respiratory syncytial virus (RSV) contributes meaningfully to adult CAP, particularly in older adults and those with chronic cardiopulmonary disease, yet is frequently underdiagnosed because clinical features overlap with other respiratory infections and routine testing is limited.Areas covered. This review summarizes key virological and immunological characteristics of RSV, highlights diagnostic challenges in adults, and discusses clinical consequences beyond respiratory illness, including cardiovascular complications, severe in-hospital outcomes, and secondary bacterial infection with antibiotic exposure. Using Korean and international data, we emphasize the value of multi-specimen molecular testing to improve detection and discuss the implications for antimicrobial stewardship in CAP management. We also provide an overview of vaccine efficacy in phase 3 trials and early real-world effectiveness in older adults.Expert opinion. Reducing the adult RSV burden will require a feasible diagnostic pathway during periods of RSV circulation, strengthened surveillance that captures clinically meaningful outcomes, and targeted vaccination of high-risk populations. Ongoing post-authorization evaluation and research in immunocompromised and other high-risk groups are needed to optimize vaccination strategies and inform next-generation prevention.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.